GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue.
Read the full article on the original site.
Read Full Article